Clinical trials: Other
Malignant Solid Tumors, Other Neoplasms Solid Tumors
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial.
- Conditions
- Malignant Solid Tumors, Other Neoplasms Solid Tumors, Pediatric Solid Tumor, Refractory Solid Tumors
- Trial name
- NCT03739827
- Where
- 3 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Very Rare Tumors, Very Rare Cancers
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year.
- Conditions
- Very Rare Tumors, Very Rare Cancers, Other Solid Tumors, Solid Tumor
- Trial name
- NCT07489378
- Testing
- Natural history study of individuals with very rare tumors
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
The purpose of this study is to learn whether a computer-based support tool called DEXI (Dermoscopy EXplainable Intelligence) can help dermatologists decide whether a lesion may be melanoma, a serious type of skin cancer.
- Conditions
- Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of Skin
- Trial name
- NCT07890415
- Testing
- Clinical decision support tool
- Where
- 8 sites in United States
- Volunteers
- 14,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Diabete Mellitus, Dyslipidaemia
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Overweight and obesity, as well as periodontitis, are common public health problems with increasing prevalence. Both conditions may be linked through shared mechanisms involving chronic low-grade systemic inflammation.
- Conditions
- Diabete Mellitus, Dyslipidaemia, Chronic Kidney Disease, Psychiatric Disorder
- Trial name
- NCT07880717
- Testing
- Periodontal Examination, Questionnaire interview, Anthropometric measurements
- Where
- Thailand
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Other Gastrointestinal Disorders, Cramp, Abdominal
The Influence of Different Mood States and Emotions on the Physiologic, Metabolic, and Perceptual Responses to Feeding Before Exercise
Many athletes anecdotally report modifying their nutritional intake before competition in order to avoid gut problems, but no studies have evaluated whether emotional state impacts tolerance to pre-exercise feeding.
- Trial name
- NCT05217589
- Testing
- Funny/Amusing Video Clips, Horror/Scary Video Clips, Thrilling/Suspenseful Video Clips
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Old Dominion University
Middle Schools, School Exclusion
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
This project will test the effectiveness of the Inclusive Skill-building Learning Approach (ISLA) in reducing the use of exclusionary discipline, improving teacher practice and student outcomes, and decreasing substance misuse…
- Conditions
- Middle Schools, School Exclusion, School Community, Teaching Practices
- Trial name
- ISLA (NCT06292078)
- Testing
- Instructional Skill-Building Learning Approach (ISLA)
- Where
- 3 sites in United States
- Volunteers
- 5,076 people, healthy volunteers welcome
- Sponsor
- University of Oregon
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs
Selumetinib and Olaparib in Solid Tumors
This study has 2 phases: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose combination of selumetinib and olaparib that can be given…
- Conditions
- Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs
- Trial name
- NCT03162627
- Testing
- Selumetinib, Olaparib
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder
SV2 PET Imaging With [11C]APP311
The aim of this study is to evaluate a new SV2A tracer, [11C]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
- Conditions
- Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
- Trial name
- SV2 (NCT03995121)
- Testing
- [11C]APP311
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC)
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a…
- Conditions
- Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
- Trial name
- SPRINT (NCT04256707)
- Testing
- Selinexor 100 mg, Docetaxel, Pembrolizumab
- Where
- 11 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Karyopharm Therapeutics Inc
Schizophrenia, Schizo Affective Disorder
iTBS to Enhance Social Cognition in People With Psychosis
The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
- Trial name
- iSCIP (NCT06118268)
- Testing
- iTBS (Active)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Multiple Sclerosis, MS (Multiple Sclerosis)
At Home Use of Stimulation Suits for Managing MS Symptoms
This study is being carried out at Multiple Sclerosis (MS) centers to evaluate whether a full-body stimulation suit at home can help people with Multiple Sclerosis (pwMS) reduce symptoms like spasticity (muscle stiffness) and…
- Conditions
- Multiple Sclerosis, MS (Multiple Sclerosis), Spasticity With Multiple Sclerosis, Ataxia - Other
- Trial name
- HANDS-MS (NCT07202195)
- Testing
- electro-stimulation suit, Usual Care
- Where
- 2 sites in Belgium, Denmark
- Volunteers
- 70 people
- Sponsor
- Daphne Kos
Schizophrenia and Other Psychotic Disorders, Healthy Adult
Dysfunction of Respiratory Enzymes in Adults With Mental Illness (DREAM)
This study tested whether intravenous methylene blue changes brain activity during a working-memory task differently in adults with schizophrenia taking stable antipsychotic medication and healthy volunteers.
- Trial name
- DREAM (NCT07866833)
- Testing
- Methylene Blue
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- King's College London
Arthritis Shoulder, Post-traumatic Arthrosis of Other Joints, Upper Arm
Mirror Medacta Shoulder System Pivotal Trial
The purpose of this study is to demonstrate safety and efficacy of the Mirror Medacta Shoulder System in total shoulder arthroplasty.
- Trial name
- NCT05062252
- Testing
- Mirror Medacta Shoulder System, Medacta Shoulder System
- Where
- 2 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Medacta International SA
Breast Cancer, Corpus Uteri Cancer
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations…
- Conditions
- Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer
- Trial name
- INSPIRE (NCT07671937)
- Testing
- INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
- Where
- 3 sites in United States
- Volunteers
- 2,748 people
- Sponsor
- University of Alabama at Birmingham
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm
Individual Patient Compassionate Use of Mirdametinib
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Conditions
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases
- Trial name
- NCT05028166
- Testing
- Mirdametinib (MEK Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University